dr. o'malley on the tolerability of parp inhibitors in ovarian cancer
Published 6 years ago • 82 plays • Length 1:18Download video MP4
Download video MP3
Similar videos
-
1:11
dr. o'malley on toxicity profiles of parp inhibitors in ovarian cancer
-
0:58
dr. o’malley on the optimal use of parp inhibitors in advanced ovarian cancer
-
1:08
dr. o'malley discusses the current role of parp inhibitors in ovarian cancer
-
1:14
dr. o'malley discusses parp combinations in ovarian cancer
-
34:13
expert views on the evolving role of parp inhibitors in the treatment of ovarian cancer
-
1:29:06
the advanced ovarian cancer treatment palette: candid conversations on parp inhibitors
-
1:15
dr. o’malley on the safety profile of mirvetuximab in ovarian cancer
-
50:32
precision medicine for ovarian cancer (2021)
-
51:46
upgrading the treatment algorithm for advanced ovarian cancer
-
57:11
personalizing advanced ovarian cancer treatment with parp inhibitors and novel approaches
-
59:14
parp inhibitors in ovarian cancer: clinical updates from sgo 2023
-
5:53
adverse-effect profiles of parp inhibitors in ovarian cancer
-
0:58
dr. o’malley on the utility of mirvetuximab in ovarian cancer
-
1:08
dr. o’malley on the state of immunotherapy in ovarian cancer
-
2:05
dr. coleman on the future of parp inhibitors in ovarian cancer
-
48:28
parp inhibitors for the treatment & prevention of hereditary breast & ovarian cancer
-
2:02
dr. konecny on resistance to parp inhibitors in ovarian cancer
-
2:06
dr. konecny discusses the role of parp inhibitors in ovarian cancer
-
1:00
dr. o’malley on the forward ii phase ib study in ovarian cancer
-
1:10:07
optimizing the use of parp inhibitors in ovarian cancer
-
2:23
dr. moore on unanswered questions with parp inhibitors in ovarian cancer
-
1:14
dr. copeland on the use of parp inhibitors in ovarian cancer